Nov 14, 2023 / 03:00PM GMT
Unidentified Analyst -
Good afternoon, everyone. Day 1, Jefferies Healthcare Conference. As I was mentioning, I think this room is a lot colder, which I enjoy. I have been dying in some of these meetings, but it also means that there's a lot of people attending, and that's always great to see.
I have the pleasure of hosting the Neurocrine management team. Joining us is Kevin Gorman, CEO; Matt Abernethy, CFO. Kyle Gano, Head of BD and Strategy; and then Eric Benevich, CCO. So we've got the entire gamut here. It's quite exciting.
Questions and Answers:
Unidentified Analyst -I will start off with maybe just some opening questions because I know we're running a little behind. So I want to give you guys some credit. I saw Teva settle on INGREZZA and I'm like, they have AUSTEDO, they have a reason to settle. Then Lupin settles. Now everyone has seemingly settled for your multibillion-dollar drug, INGREZZA, and you seemingly have patent life out to 2038. Really, really well done. The market has not necessarily given you credit. And I think part of that might be, there
Trustpilot
